JNJ

190.24

-0.95%↓

ABT

126.9

+0.4%↑

MDT

93.54

-0.98%↓

VEEV

294.34

+1.41%↑

A

147.53

+0.45%↑

JNJ

190.24

-0.95%↓

ABT

126.9

+0.4%↑

MDT

93.54

-0.98%↓

VEEV

294.34

+1.41%↑

A

147.53

+0.45%↑

JNJ

190.24

-0.95%↓

ABT

126.9

+0.4%↑

MDT

93.54

-0.98%↓

VEEV

294.34

+1.41%↑

A

147.53

+0.45%↑

JNJ

190.24

-0.95%↓

ABT

126.9

+0.4%↑

MDT

93.54

-0.98%↓

VEEV

294.34

+1.41%↑

A

147.53

+0.45%↑

JNJ

190.24

-0.95%↓

ABT

126.9

+0.4%↑

MDT

93.54

-0.98%↓

VEEV

294.34

+1.41%↑

A

147.53

+0.45%↑

Search

MacroGenics Inc

Avatud

SektorTervishoid

1.85 -2.63

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.8199999999999998

Max

1.9

Põhinäitajad

By Trading Economics

Sissetulek

4.8M

-36M

Müük

9M

22M

Kasumimarginaal

-162.992

Töötajad

341

EBITDA

5.7M

-33M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+104.92% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

4. nov 2025

Turustatistika

By TradingEconomics

Turukapital

15M

108M

Eelmine avamishind

4.48

Eelmine sulgemishind

1.85

Uudiste sentiment

By Acuity

50%

50%

163 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

MacroGenics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. okt 2025, 20:49 UTC

Tulu

Correction to Thermo Fisher Article on Oct. 22

23. okt 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23. okt 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. okt 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23. okt 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23. okt 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23. okt 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23. okt 2025, 22:49 UTC

Omandamised, ülevõtmised, äriostud

How Trump Sparked a New Era of State Capitalism -2-

23. okt 2025, 22:49 UTC

Omandamised, ülevõtmised, äriostud

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23. okt 2025, 22:17 UTC

Tulu

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23. okt 2025, 21:41 UTC

Tulu

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23. okt 2025, 21:05 UTC

Tulu

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23. okt 2025, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

23. okt 2025, 20:50 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

23. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. okt 2025, 20:35 UTC

Tulu

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23. okt 2025, 20:28 UTC

Tulu

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23. okt 2025, 20:15 UTC

Market Talk
Tulu

Global Commodities Roundup: Market Talk

23. okt 2025, 20:10 UTC

Tulu

Newmont Mining 3Q Adj EPS $1.71

23. okt 2025, 20:10 UTC

Tulu

Newmont Mining 3Q Sales $5.52B

23. okt 2025, 20:10 UTC

Tulu

Newmont Mining 3Q EPS $1.67

23. okt 2025, 20:09 UTC

Tulu

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23. okt 2025, 20:07 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

23. okt 2025, 20:07 UTC

Market Talk
Tulu

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23. okt 2025, 20:07 UTC

Tulu

Blackstone Looks to IPOs for Investment Exits -- Update

23. okt 2025, 20:05 UTC

Tulu

Intel 3Q Gross Margin 38.2% >INTC

23. okt 2025, 20:04 UTC

Tulu

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23. okt 2025, 20:04 UTC

Tulu

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23. okt 2025, 20:04 UTC

Tulu

Intel: 4Q Guidance Excludes Altera >INTC

23. okt 2025, 20:04 UTC

Tulu

Intel Sees 4Q Adj EPS 8c >INTC

Võrdlus sarnastega

Hinnamuutus

MacroGenics Inc Prognoos

Hinnasiht

By TipRanks

104.92% tõus

12 kuu keskmine prognoos

Keskmine 3.75 USD  104.92%

Kõrge 5 USD

Madal 3 USD

Põhineb 6 Wall Streeti analüütiku instrumendi MacroGenics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

3

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.47 / 1.64Toetus ja vastupanu

Lühikene perspektiiv

Neutral Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

163 / 371 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
help-icon Live chat